Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients.

Lee HS, Kweon YO, Tak WY, Park SY, Kang EJ, Lee YL, Yang HM, Park HW.

Clin Mol Hepatol. 2013 Jun;19(2):148-55. doi: 10.3350/cmh.2013.19.2.148. Epub 2013 Jun 27.

2.
3.

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.

Kim KH, Jang BK, Chung WJ, Hwang JS, Kweon YO, Tak WY, Lee HJ, Lee CH, Suh JI.

Korean J Hepatol. 2011 Sep;17(3):220-5. doi: 10.3350/kjhep.2011.17.3.220.

4.

High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.

Gheorghe L, Iacob S, Grigorescu M, Sporea I, Sirli R, Damian D, Gheorghe C, Iacob R.

J Gastrointestin Liver Dis. 2009 Mar;18(1):51-6.

5.

Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.

Tohra SK, Taneja S, Ghosh S, Sharma BK, Duseja A, Dhiman RK, Das A, Chawla YK.

Dig Dis Sci. 2011 Aug;56(8):2449-55. doi: 10.1007/s10620-011-1770-3. Epub 2011 Jun 25.

PMID:
21706207
6.
7.

Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.

Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, Kim BK, Kim SU, Ahn SH, Han KH.

Dig Dis Sci. 2015 Feb;60(2):573-81. doi: 10.1007/s10620-014-3361-6. Epub 2014 Sep 19.

PMID:
25236421
8.

Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.

Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Iio S, Oshita M, Hagiwara H, Mita E, Inui Y, Hijioka T, Inada M, Tamura S, Yoshihara H, Inoue A, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Hayashi N, Takehara T.

J Gastroenterol. 2014 Apr;49(4):737-47. doi: 10.1007/s00535-013-0824-z. Epub 2013 May 21.

PMID:
23689988
9.

Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.

Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S.

Eur J Gastroenterol Hepatol. 2013 Jul;25(7):798-805. doi: 10.1097/MEG.0b013e32835eb8bf.

PMID:
23395996
10.

Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C.

Yu JW, Sun LJ, Kang P, Yan BZ, Zhao YH.

Hepatobiliary Pancreat Dis Int. 2012 Apr;11(2):185-92.

PMID:
22484588
11.

Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients.

Kim YJ, Jang BK, Kim ES, Park KS, Cho KB, Chung WJ, Hwang JS.

Korean J Hepatol. 2012 Mar;18(1):41-7. doi: 10.3350/kjhep.2012.18.1.41. Epub 2012 Mar 22.

12.

Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.

Valenti L, Aghemo A, Stättermayer AF, Maggioni P, De Nicola S, Motta BM, Rumi MG, Dongiovanni P, Ferenci P, Colombo M, Fargion S.

Aliment Pharmacol Ther. 2012 Jun;35(12):1434-42. doi: 10.1111/j.1365-2036.2012.05109.x. Epub 2012 Apr 24.

13.

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.

Rosen I, Kori M, Eshach Adiv O, Yerushalmi B, Zion N, Shaoul R.

World J Gastroenterol. 2013 Feb 21;19(7):1098-103. doi: 10.3748/wjg.v19.i7.1098.

14.

Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin.

Chu CJ, Lee SD, Hung TH, Lin HC, Hwang SJ, Lee FY, Lu RH, Yu MI, Chang CY, Yang PL, Lee CY, Chang FY.

Aliment Pharmacol Ther. 2009 Jan;29(1):46-54. doi: 10.1111/j.1365-2036.2008.03823.x. Epub 2008 Aug 1.

15.

A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.

Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W.

Eur J Gastroenterol Hepatol. 2013 May;25(5):601-5. doi: 10.1097/MEG.0b013e32835cc899.

PMID:
23263720
16.

Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.

Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ.

Int J Infect Dis. 2011 Nov;15(11):e740-6. doi: 10.1016/j.ijid.2011.05.018. Epub 2011 Jul 30.

17.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

18.

High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice.

Heo NY, Lim YS, Lee HC, Lee YS, Kim KM, Byun KS, Han KH, Lee KS, Paik SW, Yoon SK, Suh DJ.

Clin Mol Hepatol. 2013 Mar;19(1):60-9. doi: 10.3350/cmh.2013.19.1.60. Epub 2013 Mar 25.

19.

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study.

Silva GF, Villela-Nogueira CA, Mello CE, Soares EC, Coelho HS, Ferreira PR, Ruiz FJ; Brazilian HCV-Related Advanced Fibrosis Study Group.

Braz J Infect Dis. 2014 Jan-Feb;18(1):48-52. doi: 10.1016/j.bjid.2013.05.007. Epub 2013 Sep 20.

20.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356

Supplemental Content

Support Center